Home › Compare › DNDDF vs ABBV
DNDDF yields 1941.75% · ABBV yields 3.06%● Live data
📍 DNDDF pulled ahead of the other in Year 1
Combined, DNDDF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DNDDF + ABBV for your $10,000?
Dundee Sustainable Technologies Inc. engages in the development and commercialization of technologies for the treatment of refractory materials in the mining industry in Canada and internationally. It focuses on the commercialization of CLEVR process, which extracts precious metals, as well as removes and stabilizes contaminants, such as arsenic, antimony, and cadmium; and GlassLock process, which stabilizes arsenic, forms scorodite, and produces an insoluble glass residue that meets environmental requirements. The company extracts precious and base metals from ores, concentrates, and tailings. It also provides technical services to customers in the mining industry to evaluate processing alternatives. The company was formerly known as Nichromet Extraction Inc. and changed its name to Dundee Sustainable Technologies Inc. in January 2014. The company was incorporated in 1997 and is headquartered in Montreal, Canada. Dundee Sustainable Technologies Inc. is a subsidiary of Dundee Corporation.
Full DNDDF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.